MRD negativity after end of induction in the phase 3 PhALLCON trial: A post hoc analysis.


Por: Aldoss, I, Vachhani, P, Kantarjian, HM, Montesinos, P, Leonard, JT, Gomez-Almaguer, D, Baer, MR, Gambacorti-Passerini, C, McCloskey, JK, Minami, Y, Papayannidis, C, Rocha, VG, Rousselot, P, Wang, ES, Yang, L, Hennessy, M, Vorog, A, Patel, N, Ribera-Santasusana, JM and Jabbour, E

Publicada: 1 jun 2025
Resumen:


Filiaciones:
City Hope Duarte, Duarte, CA USA
Univ Alabama Birmingham, Birmingham, AL USA
Univ Texas MD Anderson Canc Ctr, Houston, TX USA
Hosp Univ & Politecn La Fe Valencia, Valencia, Spain
Oregon Hlth & Sci Univ, Portland, OR USA
Hosp Univ, UANL, Dr Jose Eleuterio Gonzalez, Monterrey, Mexico
Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD USA
Univ Milano Bicocca, Monza, Italy
Hackensack Univ, Med Ctr, Hackensack, NJ USA
Natl Canc Ctr Hosp East, Kashiwa, Japan
IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy
Univ Sao Paulo, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
Univ Versailles St Quentin En Yvelines, Hosp Mignot, Paris, France
Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
Takeda Dev Ctr Amer Inc, Cambridge, MA USA
ICO Hosp Germans Trias i Pujol, Badalona, Spain
ISSN: 0732183X





JOURNAL OF CLINICAL ONCOLOGY
Editorial
American Society of Clinical Oncology, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA, Estados Unidos America
Tipo de documento: Meeting Abstract
Volumen: 43 Número: 16_SUPPL
Páginas:
WOS Id: 001690334500017
imagen Bronze

MÉTRICAS